

Image

LET.

164



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

SHIGHLANDER@FULBRIGHT.COM
PARTNER
DIRECT DIAL: (512) 536-3184

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

March 16, 2004

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
March 16, 2004 Date	 Steven L. Highlander

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: Serial Number 10,028,741 entitled "METHOD FOR MONITORING COAGULABILITY AND HYPERCOAGULABLE STATES" by Shinichiro Kurosawa et al.
Our ref: OMRF:004US

Commissioner:

Enclosed for filing in the above-referenced patent application is:

1. Amendment and Request for Reconsideration Under 37 C.F.R. §1.111;
2. Supplemental Information Disclosure Statement;
3. A check for \$180.00 for filing of Supplemental Information Disclosure Statement; and
4. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

If the check is inadvertently omitted, or the amount is insufficient, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or

The PTO did not receive the following listed item(s): a check for \$180.00

25390864.1 / 10111616


COMMISSIONER FOR PATENTS

March 16, 2004

Page 2

should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski L.L.P. Account No.: 50-1212/OMRF:004US/SLH.

Very truly yours,



Steven L. Highlander

SLH/cpj

Encl: As noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Shinichiro Kurosawa
Deborah J. Stearns-Kurosawa

Serial No.: 10/028,741

Filed: December 20, 2001

For: METHOD FOR MONITORING
COAGULABILITY AND
HYPERCOAGULABLE STATES

Group Art Unit: 1646

Examiner: Claire M. Kaufman

Atty. Dkt. No.: OMRP:004US

**CERTIFICATE OF MAILING
37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

March 16, 2004

Date

Steven L. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS DD
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

03/22/2004 CNGUYEN 00000135 501212 10028741

25394609.1

01 FC:1806


180.00 DA

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed herewith. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/OMRF:004US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: March 16, 2004

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

OMRF:004US

Serial No.

10/028,741

Applicant

Shinichiro Kurosawa

Deborah J. Stearns-Kurosawa

Filing Date:

December 20, 2001

Group:

1646

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C20	Abraham <i>et al.</i> , "Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial," <i>JAMA</i> , 273(12):934-941, 1995.
	C21	Barthold, "'Muromics': genomics from the perspective of the laboratory mouse," <i>Comparative Medicine</i> , 52(3):206-223, 2002.
	C22	Coughlin, "Protease-activated receptors in vascular biology," <i>Thromb. Haemost.</i> , 86:296-307, 2001
	C23	Deitch, "Animal models of sepsis and shock: a review and lessons learned," <i>Shock</i> , 9(1):1-11, 1998.
	C24	Fiedler <i>et al.</i> , "Monoclonal antibody to tumor necrosis factor- α prevents lethal endotoxin sepsis in adult rhesus monkeys," <i>J. Lab. Clin. Med.</i> , 120:574-588, 1992.
	C25	Giudici <i>et al.</i> , "Antithrombin replacement in patients with sepsis and septic shock," <i>Haematologica</i> , 84:452-460, 1999.
	C26	Gu <i>et al.</i> , "Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo," <i>Blood</i> , 95(5):1687-1693, 2000.
	C27	Hinshaw <i>et al.</i> , "Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF α)," <i>Circulatory Shock</i> , 30:279-292, 1990.

25394606.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

List of Patents and Publications for Applicant

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

OMRF:004US

Serial No.

10/028,741

Applicant

Shinichiro Kurosawa

Deborah J. Stearns-Kurosawa

Filing Date:

December 20, 2001

Group:

1646

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C28	McCloskey <i>et al.</i> , "Treatment of septic shock with human monoclonal antibody HA-1A," <i>Ann. Intern. Med.</i> , 121:1-5, 1994.
	C29	Minnema <i>et al.</i> , "Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with <i>Escherichia coli</i> ," <i>Blood</i> , 95(4):1117-1123, 2000.
	C30	Moayeri <i>et al.</i> , "Bacillus anthracis lethal toxin induces TNF- α -independent hypoxia-mediated toxicity in mice," <i>J. Clin. Invest.</i> , 112(5):670-682, 2003.
	C31	Taylor <i>et al.</i> , "Antithrombin-III prevents the lethal effects of <i>Escherichia coli</i> infusion in baboons," <i>Circulatory Shock</i> , 26:227-235, 1988.
	C32	Tracey <i>et al.</i> , "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," <i>Nature</i> , 330:662-664, 1987.
	C33	Tracey <i>et al.</i> , "Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog," <i>Surg. Gynec. Obst.</i> , 164:415-422, 1987.
	C34	Vincent <i>et al.</i> , "Clinical trials of immunomodulatory therapies in severe sepsis and septic shock," <i>CID</i> , 34:1084-1093, 2002.
	C35	Zeni <i>et al.</i> , "Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment," <i>Critical Care Medicine</i> , 25(7):1095-1110, 1997.

25394606.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)